Advertisement
UK markets closed
  • NIKKEI 225

    39,341.54
    -325.53 (-0.82%)
     
  • HANG SENG

    17,716.47
    -373.46 (-2.06%)
     
  • CRUDE OIL

    81.44
    +0.54 (+0.67%)
     
  • GOLD FUTURES

    2,337.40
    +24.20 (+1.05%)
     
  • DOW

    39,233.20
    +105.40 (+0.27%)
     
  • Bitcoin GBP

    48,822.39
    +540.88 (+1.12%)
     
  • CMC Crypto 200

    1,289.46
    +23.31 (+1.84%)
     
  • NASDAQ Composite

    17,867.61
    +62.46 (+0.35%)
     
  • UK FTSE All Share

    4,460.27
    -20.39 (-0.46%)
     

Here's Why We Think Molina Healthcare (NYSE:MOH) Is Well Worth Watching

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks' without any revenue, let alone profit. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. Loss-making companies are always racing against time to reach financial sustainability, so investors in these companies may be taking on more risk than they should.

So if this idea of high risk and high reward doesn't suit, you might be more interested in profitable, growing companies, like Molina Healthcare (NYSE:MOH). While profit isn't the sole metric that should be considered when investing, it's worth recognising businesses that can consistently produce it.

View our latest analysis for Molina Healthcare

How Quickly Is Molina Healthcare Increasing Earnings Per Share?

The market is a voting machine in the short term, but a weighing machine in the long term, so you'd expect share price to follow earnings per share (EPS) outcomes eventually. That makes EPS growth an attractive quality for any company. Molina Healthcare managed to grow EPS by 14% per year, over three years. That's a pretty good rate, if the company can sustain it.

ADVERTISEMENT

Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. Molina Healthcare maintained stable EBIT margins over the last year, all while growing revenue 10.0% to US$35b. That's a real positive.

The chart below shows how the company's bottom and top lines have progressed over time. For finer detail, click on the image.

earnings-and-revenue-history
earnings-and-revenue-history

You don't drive with your eyes on the rear-view mirror, so you might be more interested in this free report showing analyst forecasts for Molina Healthcare's future profits.

Are Molina Healthcare Insiders Aligned With All Shareholders?

We would not expect to see insiders owning a large percentage of a US$18b company like Molina Healthcare. But we do take comfort from the fact that they are investors in the company. Indeed, they have a considerable amount of wealth invested in it, currently valued at US$199m. This suggests that leadership will be very mindful of shareholders' interests when making decisions!

Should You Add Molina Healthcare To Your Watchlist?

As previously touched on, Molina Healthcare is a growing business, which is encouraging. To add an extra spark to the fire, significant insider ownership in the company is another highlight. These two factors are a huge highlight for the company which should be a strong contender your watchlists. Of course, just because Molina Healthcare is growing does not mean it is undervalued. If you're wondering about the valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.

Although Molina Healthcare certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with more skin in the game, then check out this handpicked selection of companies that not only boast of strong growth but have strong insider backing.

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com